Background: Corticotropin-releasing factor (CRF) orchestrates our body's response to stressful stimuli. Pain is often stressful and counterbalanced by activation of CRF receptors along the nociceptive pathway, although the involvement of the CRF receptors of subtypes 1 and/or 2 (CRF-R1 and CRF-R2, respectively) in CRF-induced analgesia remains controversial.Methods: This study aimed to examine CRF-R1 and CRF-R2 expression within spinal cord of rats with Freund's complete adjuvant-induced

more »

... inflammation using reverse transcriptase polymerase chain reaction, Western blot, radioligand binding, and immunofluorescence confocal analysis, Western blot, immunohistochemistry, and radioligand binding. Moreover, paw pressure algesiometry examined antinociceptive effects of intrathecal (i.t.) CRF and their possible antagonism through CRF-R1 and/or CRF-R2 selective antagonists as well as opioid receptor antagonist naloxone.Results: Our results demonstrated mainly CRF-R2 mRNA, protein, binding sites and immunoreactivity in dorsal horn of rat spinal cord. In parallel, i.t. low, systemically inactive doses of CRF as well as CRF-R2 agonists elicited potent antinociceptive effects which are dose-dependent and antagonized exclusively by i.t. CRF-R2 (K41498), but not CRF-R1 (NBI35965) antagonist. Moreover, i.t. CRF elicited inhibition of somatic pain that was dose-dependently reversed by the opioid antagonist naloxone. Consistently, double immunofluorescence confocal microscopy showed CRF-R2 on enkephalin (ENK) containing inhibitory interneurons in close opposition of incoming, mu-opioid receptor-immunoreactive nociceptive neurons but not on pre- nor on postsynaptic sensory neurons of the spinal cord.Conclusion: Taken together, these findings suggest that i.t. CRF or CRF-R2 agonist inhibits inflammatory somatic pain which occurs most predominantly through CRF-R2 receptors located on spinal enkephalinergic inhibitory interneurons resulting in endogenous opioid-mediated pain inhibition.